8-K: AIM ImmunoTech Regains NYSE American Listing Compliance

AIM ImmunoTech has regained compliance with NYSE American continued listing standards, resolving stockholder equity deficiencies through recent capital raises.

Summary

• AIM ImmunoTech Inc. announced on June 15, 2026, that it has received confirmation from NYSE Regulation on June 12, 2026, that the company has regained compliance with all continued listing standards of the NYSE American LLC.
• The company resolved deficiencies related to stockholder equity under Sections 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide.
• This compliance allows for the removal of the '.BC' indicator from the company's trading symbol and its removal from the list of noncompliant issuers on the NYSE American website.
• Recent capital raises contributed to resolving the stockholder equity deficiency, including approximately $3.5 million from warrant exercises, $2.4 million from a May 21, 2026, stock and warrant sale, and $2.6 million from a June 10, 2026, stock and warrant sale.
• The company believes its stockholders' equity now exceeds the $6.0 million minimum requirement.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as regaining listing compliance is crucial for market stability and investor confidence, although the company remains under monitoring.

Positives

• Regained compliance with all NYSE American continued listing standards.
• Resolved deficiencies related to stockholder equity.
• The '.BC' indicator will be removed from the trading symbol.
• Will be removed from NYSE American's list of noncompliant issuers.
• Successfully raised approximately $8.5 million in aggregate gross proceeds through warrant exercises and stock/warrant sales in May and June 2026.
• Company believes its stockholders' equity now exceeds the $6.0 million minimum requirement.

Negatives

• Previously identified deficiencies under NYSE American continued listing standards related to stockholder equity.
• The company will remain subject to NYSE American's continued listing monitoring procedures.

Risks

• Risks related to NYSE compliance.
• Clinical development risks.
• Regulatory approval risks.
• Other factors described in the Company's filings with the SEC, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.
• Potential difficulties in enforcing intellectual property rights in foreign countries.
• Lack of regulatory approval(s) for Ampligen.
• Lack of study drug for Ampligen trials.
• Lack of adequate funding for Ampligen trials.

Future Outlook

The company remains committed to maintaining strong financial discipline and governance going forward and will remain subject to NYSE American's continued listing monitoring procedures. The filing also contains forward-looking statements regarding clinical development, regulatory approval, and other factors that could cause actual results to differ materially.

Management Comments

• The Company will remain subject to NYSE Americans continued listing monitoring procedures and remains committed to maintaining strong financial discipline and governance going forward.

Industry Context

StockSavvy.ai notes that regaining compliance with exchange listing standards is a critical step for companies, especially those in the volatile biotech and pharma sectors, to maintain investor confidence and access to capital markets. This event for AIM ImmunoTech suggests successful financial restructuring or capital infusion to meet regulatory thresholds.

Stakeholder Impact

• Shareholders: Increased confidence due to regained listing compliance, potential for improved stock liquidity and reduced risk of delisting.
• Creditors: Improved financial standing may reduce perceived credit risk.
• Employees: Enhanced company stability can lead to greater job security and morale.

Next Steps

• Removal of the '.BC' indicator from the company's trading symbol.
• Removal from NYSE American's list of noncompliant issuers on its website.
• Continued adherence to NYSE American's continued listing monitoring procedures.

Key Dates

Recommendation

While regaining NYSE American compliance is a significant positive, the company remains under continued listing monitoring. Further progress in clinical development and sustained financial health are needed to warrant a stronger recommendation. Investors should monitor ongoing trial results and financial performance.

Keywords

NYSE American Compliance, AIM ImmunoTech, Stockholder Equity, Capital Raise, Form 8-K, Listing Standards, Immuno-pharma, Ampligen